Skip to main content
. Author manuscript; available in PMC: 2020 Sep 16.
Published in final edited form as: Expert Rev Clin Pharmacol. 2016 Apr 14;9(8):1091–1108. doi: 10.1586/17512433.2016.1172961

Table 2.

Key ongoing studies of new therapeutics in metastatic colorectal cancer.

Phase Treatment arms (therapeutic target) Primary end points Trial identifier
III Nintedanib (VEGFR, FGFR, PDGFR) vs. placebo PFS, OS LUME-Colon1 NCT02149108
II Sym004 (EGFR) vs. investigator’s choice therapy OS NCT02083653
II Irinotecan-cetuximab ± vemurafenib (BRAF) PFS SWOG 1406 NCT02164916
II Panitumumab + dabrafenib (BRAF) + trametinib (MEK) RR, PFS NCT01750918
II Cetuximab + aleplisib (PI3K) + encorafenib (BRAF) PFS NCT01719380
II T-DM1 (HER2) after progression on trastuzumab-lapatinib RR HERACLES-RESCUE EudraCT 2015–003275–30
II Pembrolizumab (PD-1) RR KEYNOTE-164 NCT02460198
II Ipilimumab (CTLA-4) + nivolumab (PD-1) RR CheckMate-142 NCT02060188
III MABp1 (Xilonix™; IL-1α) vs. placebo OS XCITE NCT01767857
III BBI-608 (STAT3, β-catenin, Nanog) + BSC vs. placebo +BSC OS NCT01830621
II FOLFOXIRI-bevacizumab (concurrent vs. sequential) vs. FOLFOX-bevacizumab ORR1 STEAM NCT01765582
PFS1